Prelude Therapeutics Inc Dossier - Source-backed chat

Prelude Therapeutics Inc

PRLDNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.98

Intrinsic Value $3.91median of 2 methodsbased on filings through 30 Jun 2026

Market Price $3.79Price as of 1 Oct 2026

Near fair valueIntrinsic value is 3% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $301.9M

Enterprise Value $293.2M

Shares Outstanding 91.5M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Prelude Therapeutics is a clinical-stage precision oncology company that has successfully de-risked its financial profile and sharpened its pipeline focus. By securing a $90 million underwritten offering in April 2026 and executing a strategic partnership with Incyte, the company has extended its cash runway into the second quarter of 2028. This financial stability allows Prelude to aggressively advance its high-potential, mutant-selective JAK2V617F inhibitor (PRT12396) and its first-in-class oral KAT6A degrader (PRT13722) through critical early-stage clinical milestones, presenting an attractive risk-reward profile for biotechnology investors.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets3 analysts · as of 18 Aug 2026

Low · most bearish analyst$6.00

Mean target$8.00

High · most bullish analyst$10.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$4.0020%

The bear case is triggered by clinical trial delays, adverse safety signals in the Phase 1 studies, or a decision by Incyte not to exercise its option. Such setbacks would severely depress the stock price and force the company to seek highly dilutive financing or further narrow its pipeline.

Base CaseCentral scenario

$7.0050%

The base case assumes steady execution of the Phase 1 trials for PRT12396 and PRT13722 with no major safety setbacks. The company maintains its disciplined spending, keeping its cash runway intact through 2028, while gradually achieving clinical proof-of-concept. Valuation aligns with the consensus analyst target.

Bull CaseUpside scenario

$9.0030%

The bull case is driven by rapid clinical validation of the mutant-selective JAK2V617F inhibitor (PRT12396), triggering a lucrative opt-in from Incyte, alongside positive initial safety and efficacy data from the PRT13722 KAT6A degrader trial in ER+ breast cancer. This would validate Prelude's targeted protein degradation and precision oncology platforms, driving substantial upward valuation adjustments.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Extended cash runway into Q2 2028 following a successful $90 million capital raise, providing ample operational runway.
Strategic validation and non-dilutive funding potential through the exclusive option agreement with Incyte for the JAK2 program.
Differentiated, mutant-selective approach targeting the JAK2 JH2 domain, potentially offering superior safety and efficacy over non-selective JAK inhibitors.
First-in-class potential for oral KAT6A degrader PRT13722 in ER+ breast cancer, backed by strong preclinical data presented at AACR 2026.

Key Investment Risks

High execution and clinical development risk inherent to early-stage (Phase 1) oncology assets.
Dependence on partner execution and strategic alignment (e.g., Incyte option agreement).
Intense competition in the precision oncology and targeted protein degradation spaces from larger, better-capitalized biopharmaceutical companies.

Thesis Invalidation Triggers

Unfavorable safety or toxicity profiles emerging in the Phase 1 trials of PRT12396 or PRT13722.
Termination or negative amendment of the Incyte collaboration agreement.
Significant acceleration in cash burn rate that shortens the projected runway to under 18 months before clinical proof-of-concept is reached.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.